Iconic Labs’ anti-fake news platform reaches over 1m readers in a week
says its service to counter misinformation about the coronavirus pandemic has attracted over 1 million readers in a week, causing shares to soar over 124%.
Iconic launched the non-profit ‘Infotagion: Covid-19’ last week alongside a cross-party group of current and former parliamentarians and is backed by governments and organisations.
The service combats fake news by allowing users to post screenshots of information seen on social media or elsewhere, which is then fact-checked by Collins and a team of experts.
The AIM-listed media firm said Infotagion was covered in more than 70 pieces of individual news covered by the UK's major news outlets including the BBC, ITV and the Daily Mail.
Shares in Iconic Labs skyrocketed 124.32% higher at 0.0415p during Wednesday trading.
“To receive such a response in such a short period of time just goes to show how important this service is to the public,” said John Quinlan, CEO of Iconic Labs.
The group noted Infotagion had been shared across social media nearly three thousand times and had been verified by both Facebook and Twitter.
Iconic said it was “very pleased” to be able to forge a role to counter disinformation about the current Covid-19 pandemic and that it had since been approached by a number of global organisations about potential uses for the service.
The group reported last week that it had slashed losses for the first half of its current year following growing demand for its online publishing content.
It said that with more people staying at home during the outbreak, it remains confident in witnessing ‘a long term increase in demand’ for its online publishing content and platforms.
Follow News & Updates from Iconic Labs:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.